nach oben

28.01.2025 | Der interessante Fall

Anwendung von Andexanet alfa bei akutem Subduralhämatom

verfasst von: Dr. Christian Schützner

Einloggen, um Zugang zu erhalten

Auszug

Akute Blutungen unter Therapie mit neuen oralen Antikoagulanzien (NOAK) stellen eine große Herausforderung an die behandelnden Teams dar. Dieser Artikel stellt den Fall eines akuten Subduralhämatoms unter Apixaban-Therapie vor. …

Reed M, Tadi P, Nicolas D. Andexanet Alfa“ StatPearls. 2024. https://www.ncbi.nlm.nih.gov/books/NBK519499/. Zugegriffen: 27. Nov. 2024.

Connolly SJ, Crowther M, Eikelboom JW, Gibson M, Curnutte JT. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380:1326–35.CrossRefPubMedPubMedCentral

Milling TJ Jr, Middeldorp S, Xu L, Koch B. Final study report of Andexanet alfa for major bleeding with factor Xa inhibitors. Circulation. 2023; 1026–38.

Siegal DM, Curnutte JT, Connolly SJ, Lu G. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015; 2413–24.

Panos NG, Cook AM, John S, Jones GM. Factor Xa inhibitor-related Intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates. Circulation. 2020; 1681–9.

White CM, Caroti KS, Bessada Y, Hernandez AV. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: a systematic review with meta-analysis. Pharmacotherapy. 2024; 394–408.

Piran S, Khatib R, Schulman S, Majeed A. Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv. 2019; 158–67.

Smith MN, Deloney L, Carter C, Weant KA, Eriksson EA. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. J Thromb Thrombolysis. 2019; 250–5.

Connolly SJ, Sharma M, Cohen AT, Demchuk AM. Andexanet for factor Xa inhibitor–associated acute Intracerebral hemorrhage. N Engl J Med. 2024;390:1745–55.CrossRefPubMed

10.

Barra ME, Das AS, Hayes BD, Rosenthal ES, Rosovsky RP. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost. 2020; 1637–47.

11.

Coleman CI, Dobesh PP, Danese S, Ulloa J, Lovelace B. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study. Future Cardiol. 2021; 127–35.

12.

Christensen H, Cordonnier C, Kõrv J, Lal A, Ovesen C, Purrucker JC, Toni D, Steiner T. European stroke organisation guideline on reversal of oral anticoagulants in acute Intracerebral Haemorrhage. Eur Stroke J. 2019; 294–306.

13.

Kubica J, Adamski P, Gajda R, Gasior M, Gierlotka M, Gil R. Andexanet alfa—recommendations for clinical use. Multidisciplinary experts’ standpoint. Cardiol J. 2023; 502–5.

14.

Demchuk AM, Yue P, Zotova E, Nakamya J, Xu L. Hemostatic efficacy and anti-FXa (factor Xa) reversal with Andexanet alfa in Intracranial hemorrhage: aNNEXA‑4 Substudy. Stroke. 2021; 2096–105.

Titel: Anwendung von Andexanet alfa bei akutem Subduralhämatom
verfasst von: Dr. Christian Schützner
Publikationsdatum: 28.01.2025
Verlag: Springer Vienna
Erschienen in: Anästhesie Nachrichten
Print ISSN: 2617-2127
Elektronische ISSN: 2731-3972
DOI: https://doi.org/10.1007/s44179-025-00269-3

Springer Medizin Österreich

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten